Richard Lerner | |
---|---|
Born | Richard Alan Lerner August 26, 1938 Chicago, Illinois, U.S. |
Nationality | American |
Fields | Chemistry |
Institutions |
The Scripps Research Institute Wistar Institute |
Alma mater | Stanford Medical School and Northwestern University |
Notable awards | Wolf Prize in Chemistry Prince of Asturias Award |
Richard A. Lerner (born August 26, 1938) is an American research chemist. Best known for his work on catalytic antibodies, Lerner served as President of The Scripps Research Institute (TSRI) until January 1, 2012, and is currently a member of its Skaggs Institute for Chemical Biology, in La Jolla, California.
Lerner grew up on the South Side of Chicago and excelled at chemistry and wrestling as a schoolboy. He attended Hirsch High School. After attending Northwestern University as an undergraduate, Lerner obtained an MD from Stanford Medical School in 1964 then undertook postdoctoral training at Scripps Clinic and Research Foundation, an early incarnation of the institute he would eventually lead. In the 1970s Lerner carried out research at the Wistar Institute in Philadelphia then returned to La Jolla to the now renamed Research Institute of Scripps Clinic. In 1982 he was appointed chairman of the Department of Molecular Biology, then five years later assumed the directorship. In 1991, when the TSRI was established as a nonprofit entity, Lerner became its first president.
In addition to his research into catalytic antibodies, providing a method of catalyzing chemical reactions thought impossible using classical techniques, Lerner has led extensive studies into protein structure, characterised cis-9,10-octadecenoamide, a novel lipid hormone that induces sleep, and provided the first evidence of a role for ozone in human disease. In 1967 Lerner discovered the role of anti-GBM antibodies in the pathogenesis of Goodpasture's disease. As of 2007, Lerner's résumé listed 67 patents and 403 published scientific papers.